Thyroid function and the risk of Alzheimer disease: the Framingham Study
- PMID: 18663163
- PMCID: PMC2694610
- DOI: 10.1001/archinte.168.14.1514
Thyroid function and the risk of Alzheimer disease: the Framingham Study
Abstract
Background: Clinical hypothyroidism and hyperthyroidism are recognized causes of reversible dementia, but previous studies relating thyrotropin levels to cognitive performance in clinically euthyroid persons have yielded inconsistent results.
Methods: We related serum thyrotropin concentrations measured at baseline (March 1977-November 1979) to the risk of Alzheimer disease (AD) in 1864 cognitively intact, clinically euthyroid Framingham original cohort participants (mean age, 71 years; 59% women). Sex-specific Cox proportional hazards models were constructed using tertiles of thyrotropin concentration (tertile 2 as the referent) and adjusting for age, apolipoprotein E epsilon4 allele status, educational level, plasma homocysteine level, current smoking, body mass index, prevalent stroke, and atrial fibrillation.
Results: During a mean follow-up of 12.7 years (range, 1-25 years), 209 participants (142 women) developed AD. Women in the lowest (<1.0 mIU/L) and highest (>2.1 mIU/L) tertiles of serum thyrotropin concentration were at increased risk for AD (multivariate-adjusted hazard ratio, 2.39 [95% confidence interval, 1.47-3.87] [P < .001] and 2.15 [95% confidence interval, 1.31-3.52] [P = .003], respectively) compared with those in the middle tertile. Thyrotropin levels were not related to AD risk in men. Analyses excluding individuals receiving thyroid supplementation did not significantly alter these relationships. In analyses limited to participants with serum thyrotropin levels of 0.1 to 10.0 mIU/L, the U-shaped relationship between thyrotropin level and AD risk was maintained in women but not when analyses were limited to those with thyrotropin levels of 0.5 to 5.0 mIU/L.
Conclusion: Low and high thyrotropin levels were associated with an increased risk of incident AD in women but not in men.
Figures
References
-
- Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006;20:298–301. - PubMed
-
- Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651–2662. - PubMed
-
- Suravarapu S, Bergstralh EJ, Farmer SA, Knopman DS, Jacobsen SJ, Roberts RO. Dementia and low testosterone and bioavailable testosterone levels in men: possible increased risk. Alzheimer Dis Assoc Disord. 2006;20:138–40. - PubMed
-
- Smith JS, Kiloh LG. The investigation of dementia: results in 200 consecutive admissions. Lancet. 1981;1:824–827. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01-HC-25195/HC/NHLBI NIH HHS/United States
- R01 NS017950/NS/NINDS NIH HHS/United States
- R01 AG016495/AG/NIA NIH HHS/United States
- 5R01-NS17950/NS/NINDS NIH HHS/United States
- R01 AR041398/AR/NIAMS NIH HHS/United States
- R01 AR/AG 47785/AG/NIA NIH HHS/United States
- K24 HL004334/HL/NHLBI NIH HHS/United States
- R01 AG008122/AG/NIA NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- K24 HL04334/HL/NHLBI NIH HHS/United States
- 5-R01-AG16495/AG/NIA NIH HHS/United States
- 5 R01 AG08122/AG/NIA NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- R01 AR/AG 41398/AG/NIA NIH HHS/United States
- P60 AR047785/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
